# Orchard Therapeutics

OTL-200/Libmeldy EMA-approved for MLD; OTL-203 (MPS-I Hurler) completed registrational enrolment 1 year ahead of schedule; OTL-201 (MPS-IIIA) awarded Innovation Passport (UK ILAP) April 2026.

Source: https://en.bioecon.ru/companies/orchard-therapeutics/
Updated: 2026-06-24

- Country: United Kingdom

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Regulatory approval | Libmeldy/OTL-200 is approved by the European Commission, UK MHRA, Swissmedic, and U.S. FDA (as Lenmeldy) | https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-completes-submission-biologics-license, https://orchard-tx.eu/pipeline/, https://www.orchard-tx.com/approach/pipeline/ |
| Regulatory approval | OTL-203 has received EMA PRIME designation and FDA RPD designation | https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-announces-last-patient-treated, https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-receives-ema-prime-designation-otl-203 |
| Revenue | $19.8M (2023) | https://www.globaldata.com/company-profile/orchard-therapeutics-plc/ |
| Headcount | 163 employees (2023) | https://www.globaldata.com/company-profile/orchard-therapeutics-plc/ |
| Headquarters | London, United Kingdom | https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-receives-ec-approval-libmeldytm-treatment, https://www.globaldata.com/company-profile/orchard-therapeutics-plc/ |

Independent sources: globaldata.com, ir.orchard-tx.com, orchard-tx.com, orchard-tx.eu

## Technologies

- [Personalized & regenerative medicine](https://en.bioecon.ru/technology/personalized-regenerative-medicine/)